Lionheart Health, Inc. has filed a non-provisional U.S. patent covering its Bioelectric-Enhanced Klotho Nanoflowers platform, designed for aging reversal and healthspan extension. The patent protects a therapeutic system that integrates nanoflower-format nanoparticles, bioelectric signaling sequences, and Klotho-modulating biologics to target cellular and mitochondrial drivers of aging.
The platform centers on engineered "nanoflowers"—flower-shaped hybrid nanoparticles capable of upregulating Klotho, a longevity-associated protein shown to improve brain, kidney, cardiovascular, and metabolic health. These nanoparticles also restore mitochondrial function by enhancing ATP production and reducing oxidative stress, while delivering targeted bioactive agents including peptides, plasmids, mRNA, and CRISPRa activators. The nanoflowers act as nanozyme catalysts that reduce reactive oxygen species and improve cellular resilience, enhancing regenerative signaling when activated by precise bioelectric patterns.
Howard J. Leonhardt, Founder, Lead Inventor and Chief Executive Officer of Lionheart Health, described the invention as representing the convergence of three powerful emerging technologies in biotechnology—bioelectric signaling, nanomedicine, and Klotho modulation. The company's goal is to create a system that reverses biological age at the cellular level and enhances healthspan safely, non-invasively, and affordably.
The nanoflowers are specifically engineered to respond to bioelectric fields, with the signals increasing cellular uptake of nanoflowers, improving intracellular transport, and activating the nanoflower's catalytic and genetic payloads. This synergistic relationship means nanoflowers require bioelectric activation for optimal performance, while the bioelectric component is designed to operate in the presence of the nanoflowers. Bioelectric stimulation is applied to open ion channels, improve endocytosis, direct nanoflowers toward mitochondria, and trigger therapeutic payload release.
Klotho expression increases due to both nanoflower-delivered genetic or peptide payloads and bioelectric activation of promoter and epigenetic pathways. Neither component alone can produce the full Klotho-enhancing effect, demonstrating a combined therapeutic benefit mechanism. The system is designed for system-wide healthspan improvement through mitochondrial biogenesis, reduction of cellular senescence, and stabilization of biological age markers.
Dr. Leslie Miller, Chief Medical Officer and former President of the International Society for Heart and Lung Transplantation, noted that bioelectric-enhanced Klotho nanoflowers provide a programmable, multi-modal tool to address the root causes of aging—declining energy production, rising inflammation, and loss of regenerative capacity. The filing marks a major milestone in longevity therapeutics according to company leadership.
The patent filing adds to Lionheart Health's growing intellectual property portfolio spanning bioelectric-controlled protein expression, stem-cell mobilization and tissue regeneration, mitochondrial restoration technologies, Klotho-based gene therapy and peptide therapeutics, and regenerative aesthetic and wellness platforms. Optional components include closed-loop adaptive control using sensors to measure mitochondrial markers or electrophysiological signals to adapt stimulation patterns, and multi-modal integration combining nanoflowers with bioelectric stimulation, peptides, red light, PEMF, and regenerative support including cell and gene therapy.
Lionheart Health is currently preparing for expanded clinical evaluation within its network of Lionheart Longevity & Wellness Licensed Clinics across the U.S. and internationally. The company plans to integrate bioelectric-enhanced Klotho nanoflowers into its XPRIZE Healthspan competition program. Additional information about the company's technologies can be found at www.LionheartHealthStim.com and www.LionheartLongevity.com.
